Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives Average Recommendation of "Buy" from Analysts

Key Points

• Enanta Pharmaceuticals has received an average consensus rating of "Buy" from five research analysts, with a one-year price target average set at $20.20.
• During the latest trading session, shares of Enanta declined to $7.92, with a market capitalization of $169.22 million and significant trading volume below its average.
• In its recent quarterly earnings report, Enanta exceeded expectations, reporting an EPS of ($0.85) and revenue of $18.31 million, above analyst estimates.

Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) have earned a consensus rating of "Buy" from the five ratings firms that are presently covering the stock, MarketBeat.com reports. Five equities research analysts have rated the stock with a buy rating. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $20.20.

ENTA has been the topic of a number of research analyst reports. HC Wainwright started coverage on Enanta Pharmaceuticals in a research report on Monday, July 28th. They issued a "buy" rating and a $20.00 target price on the stock. JMP Securities lifted their price target on Enanta Pharmaceuticals from $24.00 to $25.00 and gave the company a "market outperform" rating in a research note on Tuesday, August 12th. Wall Street Zen raised Enanta Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Sunday, June 22nd. Westpark Capital initiated coverage on Enanta Pharmaceuticals in a report on Tuesday, September 2nd. They issued a "buy" rating and a $24.00 target price on the stock. Finally, Evercore ISI decreased their price objective on shares of Enanta Pharmaceuticals from $20.00 to $12.00 and set an "outperform" rating for the company in a research note on Monday.

Enanta Pharmaceuticals Stock Performance

NASDAQ:ENTA traded down $0.37 during trading hours on Monday, reaching $7.92. The stock had a trading volume of 99,781 shares, compared to its average volume of 269,279. The stock has a market cap of $169.22 million, a P/E ratio of -1.83 and a beta of 0.84. Enanta Pharmaceuticals has a 12-month low of $4.09 and a 12-month high of $13.37. The stock has a 50 day simple moving average of $7.86 and a 200 day simple moving average of $6.78.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last issued its quarterly earnings results on Monday, August 11th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.25) by $0.40. Enanta Pharmaceuticals had a negative return on equity of 89.02% and a negative net margin of 141.98%.The firm had revenue of $18.31 million during the quarter, compared to analyst estimates of $16.21 million. On average, equities analysts expect that Enanta Pharmaceuticals will post -4.65 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Enanta Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Farther Finance Advisors LLC raised its holdings in shares of Enanta Pharmaceuticals by 11,558.0% during the second quarter. Farther Finance Advisors LLC now owns 5,829 shares of the biotechnology company's stock valued at $44,000 after acquiring an additional 5,779 shares during the period. US Bancorp DE acquired a new stake in shares of Enanta Pharmaceuticals during the 1st quarter worth about $36,000. GAMMA Investing LLC bought a new stake in Enanta Pharmaceuticals during the 1st quarter worth about $40,000. Wealth Enhancement Advisory Services LLC bought a new stake in Enanta Pharmaceuticals during the 2nd quarter worth about $88,000. Finally, Squarepoint Ops LLC bought a new position in shares of Enanta Pharmaceuticals in the 4th quarter valued at about $66,000. Institutional investors own 94.99% of the company's stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.